类风湿关节炎患者乙肝检测实践模式:美国与台湾跨区域比较
本研究基于美国与台湾两个队列的回顾性数据,比较了类风湿关节炎(RA)患者开始使用改善病情抗风湿药(DMARDs)时乙肝病毒(HBV)检测率与实践模式。美国检测率为20.3%,台湾为24.5%,两者均随时间上升但仍处低位,台湾随访期间检测率比美国高17%(粗率比1.17,95%CI 1.12-1.22)。
要点
- 美国与台湾RA患者起始DMARDs时HBV总体检测率分别为20.3%与24.5%,尽管十年间上升但整体仍低。
- 台湾随访期间HBV检测率较美国高17%(粗率比1.17,95%CI 1.12-1.22)。
- 接受检测者中,美国43.4%使用多种HBV检测,台湾为16.3%。
核心结论
- 美国和台湾RA患者起始DMARDs时HBV检测率存在小幅差异,且过去十年虽逐渐上升但两国检测率仍低。
研究设计与样本
- 回顾性队列研究,纳入美国14,568例与台湾46,265例起始首个DMARD的RA患者,以首次使用DMARD日为索引日期,基线期为索引前1年。
主要发现
- 美国总体HBV检测率为20.3%,台湾为24.5%。
- 研究期间美国检测率从13.1%升至23.0%,台湾从16.8%升至30.0%。
- 接受检测者中,美国43.4%使用超过一种HBV检测,台湾为16.3%。
- Poisson回归显示台湾随访期间检测率比美国高17%(粗率比1.17,95%CI 1.12-1.22)。
关键数值与推荐
- HBV检测定义为索引日期前1年或后1年内任何以下检测:乙肝表面抗原、表面抗体、核心抗体、e抗原、e抗体或HBV DNA。
临床怎么用
- 提示风湿免疫科医生在RA患者起始DMARDs时应关注HBV检测,尤其两国检测率均偏低,需提高筛查意识。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The hepatitis B virus (HBV) testing rates and patterns in rheumatoid arthritis (RA) patients starting disease-modifying antirheumatic drugs (DMARDs) have not been well studied. We describe and compare the practice patterns of HBV testing among RA patients in the US and Taiwan. METHODS: We conducted a retrospective cohort study, including RA patients starting a first DMARD in the US or Taiwan. The first date patients newly received any DMARD was defined as the index date, and the 1-year period before the index date was the baseline period. HBV testing was defined as any of the following tests 1 year before or after the index date: hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B core antibody, hepatitis B envelope antigen, hepatitis B envelope antibody, or HBV DNA. We calculated the HBV testing rate by year and used Poisson regression to calculate the testing rate ratio. RESULTS: We identified 14,568 RA patients in the US and 46,265 in Taiwan. The overall testing rate was 20.3% in the US and 24.5% in Taiwan, and gradually increased over the study period from 13.1-23.0% in the US and 16.8-30.0% in Taiwan. More than one type of HBV test was used in 43.4% of patients in the US and 16.3% of patients in Taiwan receiving tests. Results of Poisson regression found Taiwan had a 17% higher testing rate over the US during the followup period (crude rate ratio 1.17 [95% confidence interval 1.12-1.22]). CONCLUSION: We found small differences in the HBV testing rates across the US and Taiwan. Although the rate gradually increased in the past decade, it remained low in both countries.
引用
- Lin TC, Hashemi N, Kim SC, et al. Practice Pattern of Hepatitis B Testing in Rheumatoid Arthritis Patients: A Cross-National Comparison Between the US and Taiwan. Arthritis Care Res (Hoboken). 2017. PMID: 28320050. doi:10.1002/acr.23241
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。